Chemistry:Meglumine antimoniate
 | |
| Clinical data | |
|---|---|
| Other names | Meglumine antimonate |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| NIAID ChemDB | |
| Chemical and physical data | |
| Formula | Variable |
| Molar mass | Variable |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]
Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]
Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines.[3] It is available in Southern Europe and Latin America but not the United States.[4][5]
Society and culture
It is manufactured by Aventis[6] and sold as Glucantime in France , and Glucantim in Italy.
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 WHO Model Formulary 2008. World Health Organization. 2009. p. 183. ISBN 9789241547659.
- ↑ "Chemical Medicines" (in en). Drug Discovery: A History. John Wiley & Sons. 2005. p. 59. ISBN 9780470015520. https://books.google.com/books?id=jglFsz5EJR8C&pg=PA59.
- ↑ World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "Antiparasitic Drugs" (in en). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. 2010. p. 95. ISBN 978-1437735727. https://books.google.com/books?id=pxnKBrfwTFYC&pg=PT128.
- ↑ (in en) Infectious Diseases. Lippincott Williams & Wilkins. 2004. p. 355. ISBN 9780781733717. https://books.google.com/books?id=91altE1evAsC&pg=PA355.
- ↑ "Sanofi-Aventis Bekräftigt Seine Verpflichtung Zur Sicherstellung Des Zugangs Zu Medikamenten in Den "Südlichen Ländern" Mit Einer Politik Der Gestaffelten Arzneimittelpreise Je Nach Bevölkerungseinkommen" (in de). Aventis press release. 15 April 2005. http://www.sanofi.de/l/de/de/layout.jsp?cnt=38A41931-0260-4715-A7C3-25AD268B9C27.
External links
- "Meglumine antimoniate". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/meglumine%20antimoniate.
 |  |
